Overview

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Status:
Active, not recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

This is a phase III, randomized, double-blinded, comparative, multi-centre study to assess the efficacy of atezolizumab in combination with platinum-based chemotherapy plus bevacizumab administered concurrent to chemotherapy and in maintenance, in patients presenting epithelial ovarian cancer (including patients with primary peritoneal and / or fallopian tube adenocarcinoma) who have platinum-sensitive relapse (platinum-free interval > 6 months).

Phase:

Phase 3

Details

Lead Sponsor:

ARCAGY/ GINECO GROUP

Collaborator:

Hoffmann-La Roche

Treatments:

Antibodies, Monoclonal
Atezolizumab
Bevacizumab
Doxorubicin
Liposomal doxorubicin